

Erin E Salo-Mullen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6990268/publications.pdf>

Version: 2024-02-01

42
papers

1,894
citations

394421
19
h-index

289244
40
g-index

43
all docs

43
docs citations

43
times ranked

3191
citing authors

#	ARTICLE	IF	CITATIONS
1	Factors Influencing Patient Preferences for Telehealth Cancer Genetic Counseling During the COVID-19 Pandemic. JCO Oncology Practice, 2022, 18, e462-e471.	2.9	8
2	Multiple Primary Cancers in Patients Undergoing Tumor-Normal Sequencing Define Novel Associations. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 362-371.	2.5	7
3	Early age of onset and broad cancer spectrum persist in MSH6- and PMS2-associated Lynch syndrome. Genetics in Medicine, 2022, 24, 1187-1195.	2.4	7
4	Resolving pathogenicity classification for the CDH1 c.[715G>A] (p.Gly239Arg) Variant. European Journal of Human Genetics, 2021, 29, 1103-1109.	2.8	1
5	Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors. Nature Cancer, 2021, 2, 357-365.	13.2	74
6	Prevalence and Characterization of Biallelic and Monoallelic <i>NTHL1</i> and <i>MSH3</i> Variant Carriers From a Pan-Cancer Patient Population. JCO Precision Oncology, 2021, 5, 455-465.	3.0	10
7	Early-Onset Pancreas Cancer: Clinical Descriptors, Genomics, and Outcomes. Journal of the National Cancer Institute, 2021, 113, 1194-1202.	6.3	35
8	Insertion of an <i>SVA</i> element in <i>MSH2</i> as a novel cause of Lynch syndrome. Genes Chromosomes and Cancer, 2021, 60, 571-576.	2.8	6
9	Disparities in pan-cancer patients undergoing germline cancer risk assessment by self-reported race/ethnicity and ancestry.. Journal of Clinical Oncology, 2021, 39, 10508-10508.	1.6	2
10	Paired Tumor-Normal Sequencing Provides Insights into TP53-Related Cancer Spectrum in Li-Fraumeni Patients. Journal of the National Cancer Institute, 2021, , .	6.3	6
11	Uptake and acceptability of a mainstreaming model of hereditary cancer multigene panel testing among patients with ovarian, pancreatic, and prostate cancer. Genetics in Medicine, 2021, 23, 2105-2113.	2.4	29
12	A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers. Journal of the National Cancer Institute, 2021, 113, 1683-1692.	6.3	66
13	Therapeutic Implications of Germline Testing in Patients With Advanced Cancers. Journal of Clinical Oncology, 2021, 39, 2698-2709.	1.6	83
14	Pancreas cancer and <i>BRCA</i> : A critical subset of patients with improving therapeutic outcomes. Cancer, 2021, 127, 4393-4402.	4.1	24
15	Genetic Factors. , 2020, , 180-208.e11.		4
16	Insertion of an Alu-like element in <i>MLH1</i> intron 7 as a novel cause of Lynch syndrome. Molecular Genetics & Genomic Medicine, 2020, 8, e1523.	1.2	4
17	Mismatch Repair-Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy. Clinical Cancer Research, 2020, 26, 3271-3279.	7.0	118
18	Risk of Metachronous Colorectal Neoplasm after a Segmental Colectomy in Lynch Syndrome Patients According to Mismatch Repair Gene Status. Journal of the American College of Surgeons, 2020, 230, 669-675.	0.5	16

#	ARTICLE	IF	CITATIONS
19	An Emerging Paradigm for Germline Testing in Pancreatic Ductal Adenocarcinoma and Immediate Implications for Clinical Practice. <i>JAMA Oncology</i> , 2020, 6, 764.	7.1	35
20	Indications for Total Gastrectomy in <i>CDH1</i> Mutation Carriers and Outcomes of Risk-Reducing Minimally Invasive and Open Gastrectomies. <i>JAMA Surgery</i> , 2020, 155, 1050.	4.3	34
21	Outcome of Pancreatic Cancer Surveillance Among High-Risk Individuals Tested for Germline Mutations in <i>BRCA1</i> and <i>BRCA2</i> . <i>Cancer Prevention Research</i> , 2019, 12, 599-608.	1.5	6
22	Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1067-1074.	6.3	170
23	Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. <i>Clinical Cancer Research</i> , 2018, 24, 1326-1336.	7.0	281
24	Contiguous gene deletion of chromosome 2p16.3-p21 as a cause of Lynch syndrome. <i>Familial Cancer</i> , 2018, 17, 71-77.	1.9	10
25	Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma. <i>European Journal of Cancer</i> , 2018, 89, 19-26.	2.8	125
26	Psychosocial factors associated with the uptake of contralateral prophylactic mastectomy among BRCA1/2 mutation noncarriers with newly diagnosed breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 297-306.	2.5	16
27	Educational and Psychosocial Support Needs in Lynch Syndrome: Implementation and Assessment of an Educational Workshop and Support Group. <i>Journal of Genetic Counseling</i> , 2017, 26, 232-243.	1.6	14
28	CDH1 Missense Variant c.1679C>G (p.T560R) Completely Disrupts Normal Splicing through Creation of a Novel 5' Splice Site. <i>PLoS ONE</i> , 2016, 11, e0165654.	2.5	16
29	Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 1-13.	3.0	39
30	Genome Sequencing of Multiple Primary Tumors Reveals a Novel <i>PALB2</i> Variant. <i>Journal of Clinical Oncology</i> , 2016, 34, e61-e67.	1.6	6
31	Identification of germline genetic mutations in patients with pancreatic cancer. <i>Cancer</i> , 2015, 121, 4382-4388.	4.1	167
32	Assessment of individuals with BRCA1 and BRCA2 large rearrangements in high-risk breast and ovarian cancer families. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 625-634.	2.5	11
33	Mosaic partial deletion of the PTEN gene in a patient with Cowden syndrome. <i>Familial Cancer</i> , 2014, 13, 459-467.	1.9	14
34	Phase IB trial of cisplatin (C), gemcitabine (G), and veliparib (V) in patients with known or potential BRCA or PALB2-mutated pancreas adenocarcinoma (PC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 4023-4023.	1.6	17
35	Variable penetrance of CDH1 mutation diffuse gastric cancer: A genomic analysis.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4082-4082.	1.6	0
36	Juvenile Polyposis Syndrome Presenting With Familial Gastric Cancer and Massive Gastric Polyposis. <i>Journal of Clinical Oncology</i> , 2012, 30, e229-e232.	1.6	9

#	ARTICLE	IF	CITATIONS
37	The Prevalence of Thyroid Cancer and Benign Thyroid Disease in Patients With Familial Adenomatous Polyposis May Be Higher Than Previously Recognized. <i>Clinical Colorectal Cancer</i> , 2012, 11, 304-308.	2.3	52
38	The Genetic Counselor. <i>Advances in Surgery</i> , 2012, 46, 137-153.	1.3	2
39	Systematic Immunohistochemistry Screening for Lynch Syndrome in Early Age-of-Onset Colorectal Cancer Patients Undergoing Surgical Resection. <i>Journal of the American College of Surgeons</i> , 2012, 214, 61-67.	0.5	32
40	Prevalence of <i>BRCA1</i> and <i>BRCA2</i> mutations in Ashkenazi Jewish families with breast and pancreatic cancer. <i>Cancer</i> , 2012, 118, 493-499.	4.1	83
41	Germline <i>PALB2</i> mutation analysis in breast-pancreas cancer families. <i>Journal of Medical Genetics</i> , 2011, 48, 523-525.	3.2	28
42	An Emerging Entity: Pancreatic Adenocarcinoma Associated with a Known <i>BRCA</i> Mutation: Clinical Descriptors, Treatment Implications, and Future Directions. <i>Oncologist</i> , 2011, 16, 1397-1402.	3.7	227